Search Results - "Guo, Renhua"

Ferroptosis in cancer therapy: a novel approach to reversing drug resistance by Zhang, Chen, Liu, Xinyin, Jin, Shidai, Chen, Yi, Guo, Renhua

“…Ferroptosis is an intracellular iron-dependent form of cell death that is distinct from apoptosis, necrosis, and autophagy. Extensive studies suggest that…”
Get full text

LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer by Dai, Jiali, Qu, Tianyu, Yin, Dandan, Cui, Yanan, Zhang, Chen, Zhang, Erbao, Guo, Renhua

“…Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment prolongs the survival of lung cancer patients harbouring activating EGFR…”
Get full text

LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC by Liu, Xinyin, Lu, Xiyi, Zhen, Fuxi, Jin, Shidai, Yu, Tongfu, Zhu, Quan, Wang, Wei, Xu, Kun, Yao, Jiaqi, Guo, Renhua

“…Gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor, has been used as the first choice of treatment for advanced non-small-cell lung…”
Get full text

B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma by Cui, Yanan, Li, Jun, Zhang, Pengpeng, Yin, Dandan, Wang, Ziyu, Dai, Jiali, Wang, Wei, Zhang, Erbao, Guo, Renhua

“…Invasive adenocarcinoma (IAC), which is typically preceded by minimally invasive adenocarcinoma (MIA), is the dominant pathological subtype of early-stage lung…”
Get full text

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial by Jiang, Tao, Wang, Pingyang, Zhang, Jie, Zhao, Yanqiu, Zhou, Jianying, Fan, Yun, Shu, Yongqian, Liu, Xiaoqing, Zhang, Helong, He, Jianxing, Gao, Guanghui, Mu, Xiaoqian, Bao, Zhang, Xu, Yanjun, Guo, Renhua, Wang, Hong, Deng, Lin, Ma, Ningqiang, Zhang, Yalei, Feng, Hui, Yao, Sheng, Wu, Jiarui, Chen, Luonan, Zhou, Caicun, Ren, Shengxiang

“…This multicenter phase-II trial aimed to investigate the efficacy, safety, and predictive biomarkers of toripalimab plus chemotherapy as second-line treatment…”
Get full text

Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study by Li, Ran, Liang, Hongge, Li, Jun, Shao, Zhenyu, Yang, Donghong, Bao, Jing, Wang, Keqiang, Xi, Wen, Gao, Zhancheng, Guo, Renhua, Mu, Xinlin

“…Paclitaxel liposome (Lipusu) is known to be effective in non-small cell lung cancer (NSCLC) as first-line treatment. This study aimed to evaluate the…”
Get full text

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial by Jiang, Tao, Chen, Jianhua, Xu, Xingxiang, Cheng, Ying, Chen, Gongyan, Pan, Yueyin, Fang, Yong, Wang, Qiming, Huang, Yunchao, Yao, Wenxiu, Wang, Rui, Li, Xingya, Zhang, Wei, Zhang, Yanjun, Hu, Sheng, Guo, Renhua, Shi, Jianhua, Wang, Zhiwu, Cao, Peiguo, Wang, Donglin, Fang, Jian, Luo, Hui, Geng, Yi, Xing, Chunyan, Lv, Dongqing, Zhang, Yiping, Yu, Junyan, Cang, Shundong, Zhang, Yaxi, Zhang, Jiao, Yang, Zeyu, Shi, Wei, Zou, Jianjun, Zhou, Caicun, Ren, Shengxiang

“…Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line…”
Get full text

Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma by Wang, Yufei, Zhang, Chen, Ji, Chengyue, Jin, Wenli, He, Xin, Yu, Shunzhi, Guo, Renhua

“…Background: Recent studies have identified several molecular subtypes of lung adenocarcinoma (LUAD) that have different prognoses to help predict the efficacy…”
Get full text

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer by Cui, Yanan, Liu, Xinyin, Wu, Yuemin, Liang, Xiao, Dai, Jiali, Zhang, Zhihong, Guo, Renhua

“…Immune checkpoint inhibitors (ICIs) have exhibited promising efficacy in non-small cell lung cancer (NSCLC), but the response occurs in only a minority of…”
Get full text

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers by Dai, Jiali, Cui, Yanan, Liang, Xiao, Xu, Jiali, Li, Jun, Chen, Yu, Zhang, Erbao, Guo, Renhua

“…There has been evidence that Polybromo-1 (PBRM1) mutation was closely associated with immunotherapy response in clear cell renal cell carcinoma (ccRCC)…”
Get full text

A two-phase comprehensive NSCLC prognostic study identifies lncRNAs with significant main effect and interaction by Zhu, Jing, Guan, Jinxing, Ji, Xinyu, Song, Yunjie, Xu, Xiaoshuang, Wang, Qianqian, Zhang, Quanan, Guo, Renhua, Wang, Rui, Zhang, Ruyang

“…Long noncoding RNA (lncRNA) are involved in regulating physiological behaviors for various malignant tumors, including non-small-cell lung cancer (NSCLC)…”
Get full text

Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting by Wang, Qianqian, Gao, Wen, Gao, Fangyan, Jin, Shidai, Qu, Tianyu, Lin, Fan, Zhang, Chen, Zhang, Jingya, Zhang, Zhihong, Chen, Liang, Guo, Renhua

“…Abstract Background To compare the benefits and explore the cause of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitor…”
Get full text

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review by Chen, Xiaofeng, Liu, Yiqian, Røe, Oluf Dimitri, Qian, Yingying, Guo, Renhua, Zhu, Lingjun, Yin, Yongmei, Shu, Yongqian

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with…”
Get full text

Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study by Sun, Sibo, Liu, Yiqian, Eisfeld, Ann-Kathrin, Zhen, Fuxi, Jin, Shidai, Gao, Wen, Yu, Tongfu, Chen, Liang, Wang, Wei, Chen, Wei, Yuan, Mingming, Chen, Rongrong, He, Kai, Guo, Renhua

“…Paired tumor-normal targeted next-generation sequencing (NGS) is primarily used to identify actionable somatic mutations, but can also detect germline variants…”
Get full text

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer by Zhang, Chen, Cao, Honggang, Cui, Yanan, Jin, Shidai, Gao, Wen, Huang, Chenjun, Guo, Renhua

“…Background Acquired resistance development is a major challenge in the epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR–TKI) treatment of…”
Get full text

Molecular features of NSCLC patients with liver metastasis by Zhao, Jun, Zhong, Jia, Chen, Yujie, Chen, Zipei, Yin, Huan, He, Yuange, Chen, Rongrong, Guo, Renhua

“…Metastasis is the primary cause of lung cancer-related death. Primary cancer cells invade through the lymphatic or blood vessels to distant sites. Recently, it…”
Get full text

Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer by Xiang, Chengcheng, Jin, Shidai, Zhang, Juan, Chen, Minjian, Xia, Yankai, Shu, Yongqian, Guo, Renhua

“…Background: Lung cancer is the most common cause of cancer-related deaths in men and women worldwide. Novel diagnostic biomarkers are urgently required to…”
Get full text

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways by Wang, Xiaomeng, Xu, Jiali, Chen, Jin, Jin, Shidai, Yao, Jiaqi, Yu, Tongfu, Wang, Wei, Guo, Renhua

“…Background: The efficacy of an EGFR-targeted treatment strategy for non-small cell lung cancer (NSCLC) is reduced by drug resistance. IL-22 enhances tumor…”
Get full text

High Expression of ACE2 and TMPRSS2 at the Resection Margin Makes Lung Cancer Survivors Susceptible to SARS-CoV-2 With Unfavorable Prognosis by Wang, Qianqian, Li, Liangyu, Qu, Tianyu, Li, Jie, Wu, Lingxiang, Li, Kening, Wang, Ziyu, Zhu, Mengyan, Huang, Bin, Wu, Wei, Wu, Min, Ding, Rong, Zhang, Zhihong, Wang, Qianghu, Xia, Xinyi, Li, Pengping, Zhang, Zhi, Guo, Renhua

“…Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide. Systematic analysis of lung cancer survivors at molecular and clinical levels is warranted to…”
Get full text

Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR‐TKIs in advanced non‐small cell lung cancer: A systematic review and network meta‐analysis by Dai, Jiali, Liu, Xinyin, Li, Jun, Qu, Tianyu, Cui, Yanan, Jin, Shidai, Zhang, Erbao, Guo, Renhua

“…Background The combination of antiangiogenic agents with epidermal growth factor receptor inhibitors (EGFR‐TKIs) and chemotherapy with EGFR‐TKIs are the most…”
Get full text